Diaceutics (DXRX)

Sector:

Health Care

Index:

FTSE AIM All-Share

130.35p
   
  • Change Today:
    -3.65p
  • 52 Week High: 136.00
  • 52 Week Low: 83.50
  • Currency: UK Pounds
  • Shares Issued: 84.68m
  • Volume: 71,309
  • Market Cap: £110.38m
  • RiskGrade: 196

Diaceutics secures $2m multi-year contract with global pharma company

By Iain Gilbert

Date: Monday 13 Jun 2022

LONDON (ShareCast) - (Sharecast News) - Diagnostic commercialisation company Diaceutics has secured a multi-year contract win with an unnamed "top five" global pharmaceutical company to deliver customised data insights via its DXRX platform.
Diaceutics said on Monday that the three-year enterprise deal, valued at more than $2.0m in aggregate, was "a notable upsell win" for the group, which has been working with the client since 2014.

The AIM-listed group also said the contract supports its move towards enhanced multi-year recurring revenues, a key strategy for the company going forward.

Under the terms of the new agreement, Diaceutics will provide comprehensive mapping and analysis of US physicians and labs who perform testing for non-small cell lung cancer.

Chief commercial officer Jordan Clark said: "This win is testament to the value of our DXRX platform, proving that our platform continues to gain traction within the marketplace, elevating our profile and putting us in a prime position to continue to win large, long-term contracts.

"As the treatment of cancer has become progressively more biomarker-driven, and with the rapid emergence of effective matched targeted therapies, pharma companies are making attempts to define best practices for which tests are necessary and in what target population. The DXRX intelligence will be a vital tool in enabling our customer to achieve this and optimising their sales territories."

As of 1030 BST, Diaceutics shares were up 3.69% at 106.80p.



Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Diaceutics Market Data

Currency UK Pounds
Share Price 130.35p
Change Today -3.65p
% Change -2.72 %
52 Week High 136.00
52 Week Low 83.50
Volume 71,309
Shares Issued 84.68m
Market Cap £110.38m
RiskGrade 196

Diaceutics Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
35.96% below the market average35.96% below the market average35.96% below the market average35.96% below the market average35.96% below the market average
41.94% below the sector average41.94% below the sector average41.94% below the sector average41.94% below the sector average41.94% below the sector average
Price Trend
92.38% above the market average92.38% above the market average92.38% above the market average92.38% above the market average92.38% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Income Not Available
Growth
14.29% above the market average14.29% above the market average14.29% above the market average14.29% above the market average14.29% above the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average

Diaceutics Dividends

No dividends found

Trades for 23-Jul-2024

Time Volume / Share Price
11:33 2,239 @ 130.12p
11:00 5,000 @ 131.00p
11:00 1,000 @ 131.00p
11:00 4,000 @ 131.00p
09:01 10,000 @ 133.56p

Diaceutics Key Personnel

CEO Ryan Gerard Keeling
CFO Nick Roberts

Top of Page